{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:20:53Z","timestamp":1789035653350,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.vaccine.2008.09.011","type":"journal-article","created":{"date-parts":[[2008,9,21]],"date-time":"2008-09-21T09:22:07Z","timestamp":1221988927000},"page":"6092-6098","source":"Crossref","is-referenced-by-count":20,"title":["The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"26","author":[{"given":"Steven C.","family":"Derrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.P.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabadran","family":"Dheenadhayalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Kolibab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon L.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2008.09.011_bib1","unstructured":"World Health Organization. Global tuberculosis control-surveillance, planning, financing; 2007. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"10.1016\/j.vaccine.2008.09.011_bib2","unstructured":"World Health Organization. Fact sheet No. 104; 2002. http:\/\/www.who.int\/mediacentre\/facsheets."},{"key":"10.1016\/j.vaccine.2008.09.011_bib3","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1517\/14712598.7.11.1665","article-title":"How a different look at latency can help develop novel diagnostics and vaccines against tuberculosis","volume":"7","author":"Locht","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2008.09.011_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis Meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2008.09.011_bib5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1517\/14712598.7.10.1539","article-title":"Tuberculosis subunit vaccines: from basic science to clinical testing","volume":"7","author":"Doherty","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2008.09.011_bib6","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1016\/j.vaccine.2007.01.112","article-title":"Current status of TB vaccines","volume":"25","author":"Gupta","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.09.011_bib7","series-title":"A physicians guide to tuberculosis","author":"Isemen","year":"2000"},{"key":"10.1016\/j.vaccine.2008.09.011_bib8","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/IAI.70.4.2100-2107.2002","article-title":"Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice","volume":"70","author":"Moreira","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.09.011_bib9","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/IAI.71.4.2192-2198.2003","article-title":"Pulmonary necrosis resulting from DNA vaccination against tuberculosis","volume":"71","author":"Taylor","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.09.011_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.vaccine.2005.07.103","article-title":"Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations","volume":"24","author":"Basaraba","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.09.011_bib11","series-title":"The pathogenesis of tuberculosis","author":"Rich","year":"1951"},{"key":"10.1016\/j.vaccine.2008.09.011_bib12","first-page":"123","article-title":"The effect of BCG vaccination in naturally infected tuberculin-positive individuals","volume":"49","author":"Egmose","year":"1968","journal-title":"Scand J Resp Dis"},{"key":"10.1016\/j.vaccine.2008.09.011_bib13","first-page":"243","article-title":"BCG vaccination of tuberculosis patients and of strong reactors to tuberculin","volume":"51","author":"Narain","year":"1976","journal-title":"Bull Int Union Tuberc"},{"key":"10.1016\/j.vaccine.2008.09.011_bib14","first-page":"1110","article-title":"Adverse effects of BCG revaccination: a report on 13 cases from Rio de Janeiro, Brazil","volume":"6","author":"Cunha","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.vaccine.2008.09.011_bib15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0264-410X(99)00540-X","article-title":"The immunogenicity of single and combination DNA vaccines","volume":"18","author":"Morris","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.09.011_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.70.1.292-302.2002","article-title":"DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis","volume":"70","author":"Delogu","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.09.011_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.123.3.445","article-title":"Microbial persistence: the capacity of tubercle bacilli to survive sterilization in mouse tissues","volume":"123","author":"McCune","year":"1966","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2008.09.011_bib18","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.vaccine.2004.11.051","article-title":"Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6","volume":"23","author":"Langermans","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.09.011_bib19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.vaccine.2004.07.036","article-title":"A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity","volume":"23","author":"Derrick","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.09.011_bib20","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1128\/IAI.68.3.1706-1709.2000","article-title":"Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode","volume":"68","author":"Turner","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.09.011_bib21","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.2741\/A285","article-title":"Mycobacterial pathogenesis: a historical perspective","volume":"3","author":"Collins","year":"1998","journal-title":"Front Biosci"},{"key":"10.1016\/j.vaccine.2008.09.011_bib22","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1128\/IAI.73.6.3301-3306.2005","article-title":"Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs","volume":"73","author":"Reece","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.09.011_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tube.2005.07.002","article-title":"Safety issues regarding new vaccines against tuberculosis, with an emphasis on post-exposure vaccination","volume":"86","author":"Orme","year":"2006","journal-title":"Tuberculosis"},{"key":"10.1016\/j.vaccine.2008.09.011_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/17460913.1.1.63","article-title":"DNA vaccination against mycobacterial diseases","volume":"1","author":"Huygen","year":"2006","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2008.09.011_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/156652407780831557","article-title":"Current strategies in TB immunotherapy","volume":"7","author":"Roy","year":"2007","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.vaccine.2008.09.011_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/22326","article-title":"Therapy of tuberculosis in mice by DNA vaccination","volume":"400","author":"Lowrie","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2008.09.011_bib27","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1016\/j.vaccine.2005.05.035","article-title":"Therapeutic effect of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection","volume":"23","author":"Zhu","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.09.011_bib28","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1128\/IAI.70.7.3318-3323.2002","article-title":"DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge","volume":"70","author":"Repique","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.09.011_bib29","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1371\/journal.pone.0001052","article-title":"Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trials","volume":"2","author":"Pathan","year":"2007","journal-title":"PLOS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08012280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08012280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T09:25:04Z","timestamp":1545729904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08012280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":29,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0264410X08012280"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.09.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}